Pages that link to "Q36426816"
Jump to navigation
Jump to search
The following pages link to Clinical implications of pharmacogenomics of statin treatment (Q36426816):
Displaying 50 items.
- Genome-wide association of lipid-lowering response to statins in combined study populations (Q21142620) (← links)
- Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response (Q24632568) (← links)
- Pharmacogenomics and cardiovascular disease (Q26997380) (← links)
- The Impact of the Gut Microbiota on Drug Metabolism and Clinical Outcome (Q28071938) (← links)
- Genome-wide study of gene variants associated with differential cardiovascular event reduction by pravastatin therapy (Q28729086) (← links)
- A network pharmacology approach to evaluating the efficacy of chinese medicine using genome-wide transcriptional expression data (Q30640970) (← links)
- PharmGKB: an integrated resource of pharmacogenomic data and knowledge (Q33372157) (← links)
- The Pathway Less Traveled: Moving from Candidate Genes to Candidate Pathways in the Analysis of Genome-Wide Data from Large Scale Pharmacogenetic Association Studies (Q33440652) (← links)
- Investigating the effects of statins on cellular lipid metabolism using a yeast expression system (Q33521217) (← links)
- Molecular population genetics of PCSK9: a signature of recent positive selection. (Q33743727) (← links)
- Applied pharmacogenomics in cardiovascular medicine (Q33846255) (← links)
- Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins (Q34453666) (← links)
- Genetic variants in the KIF6 region and coronary event reduction from statin therapy (Q34467745) (← links)
- The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. (Q34613443) (← links)
- Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins (Q34680467) (← links)
- Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin (Q34787395) (← links)
- Effect of CETP polymorphism on atorvastatin lipid-regulating effect and clinical prognosis of patients with coronary heart disease (Q34852756) (← links)
- Cholesteryl ester transfer protein gene and effectiveness of lipid lowering of atorvastatin (Q35036321) (← links)
- The role of epigenetics in personalized medicine: challenges and opportunities (Q35043066) (← links)
- Apolipoprotein E mRNA expression in mononuclear cells from normolipidemic and hypercholesterolemic individuals treated with atorvastatin (Q35639536) (← links)
- Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs. (Q35762508) (← links)
- A pharmacogenetic pilot study reveals MTHFR, DRD3, and MDR1 polymorphisms as biomarker candidates for slow atorvastatin metabolizers. (Q35917726) (← links)
- The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (Q35955534) (← links)
- The SLCO1B1*5 genetic variant is associated with statin-induced side effects (Q36158024) (← links)
- Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study (Q36730132) (← links)
- Pharmacogenetics of response to statins (Q37074291) (← links)
- Association between cholesterol synthesis/absorption markers and effects of cholesterol lowering by atorvastatin among patients with high risk of coronary heart disease (Q37222727) (← links)
- The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13 ) on the effectiveness of statins: the GenHAT study (Q37240345) (← links)
- Pharmacogenomic importance of pravastatin (Q37264531) (← links)
- Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease (Q37293985) (← links)
- Pharmacogenetics of cardiovascular drug therapy (Q37430401) (← links)
- Statin regulation of CYP3A4 and CYP3A5 expression (Q37521064) (← links)
- Genetic determinants of response to statins (Q37578563) (← links)
- Transgenic mouse model reveals an unsuspected role of the acetylcholine receptor in statin-induced neuromuscular adverse drug reactions (Q37678095) (← links)
- A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application? (Q37908891) (← links)
- Pharmacogenetics of statins: achievements, whole-genome analyses and future perspectives (Q38010751) (← links)
- Pharmacogenomics of lipid-lowering therapies (Q38112823) (← links)
- Genetics and personalized medicine--a role in statin therapy? (Q38167710) (← links)
- Cardiovascular drugs and the genetic response. (Q38220502) (← links)
- Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia. (Q38663481) (← links)
- Seventeen years of statin pharmacogenetics: a systematic review (Q38670109) (← links)
- The efficacy of evolocumab in the management of hyperlipidemia: a systematic review (Q38794761) (← links)
- Sex and Race Differences in the Association Between Statin Use and the Incidence of Alzheimer Disease (Q39109470) (← links)
- Role of microRNAs 221/222 on statin induced nitric oxide release in human endothelial cells (Q39287679) (← links)
- Prevalence and Factors Associated With Statin Use Among a Nationally Representative Sample of US Adults: National Health and Nutrition Examination Survey, 2011-2012. (Q39507722) (← links)
- Effects of Different Types of Statins on Lipid Profile: A Perspective on Asians. (Q41391827) (← links)
- Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects (Q42291683) (← links)
- Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction (Q42936467) (← links)
- APOE gene polymorphisms and response to statin therapy. (Q45968013) (← links)
- Systems Pharmacology Dissection of Cholesterol Regulation Reveals Determinants of Large Pharmacodynamic Variability between Cell Lines (Q47262709) (← links)